Clinical Trial Update: RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing RC148 plus platinum-based chemotherapy versus tislelizumab plus platinum-based chemotherapy for first-line squamous non-small cell lun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• RC148 (RC148)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: RECRUITING